SUTENT 50MG 28 CAPSULES

Sunitinib was approved on January 26 2006 by FDA for the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor (GIST). Sunitinib is a small-molecule which is administered orally and it is multi-targeted receptor tyrosine kinase (RTK) inhibitor. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). sunitinib also inhibits KIT (CD117) the RTK that drives the majority of GISTs and other RTKs including RET CSF-1R and flt3.